<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03945292</url>
  </required_header>
  <id_info>
    <org_study_id>AROAAT2001</org_study_id>
    <secondary_id>2018-003385-14</secondary_id>
    <nct_id>NCT03945292</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Effect on Liver Histologic Parameters of ARO-AAT</brief_title>
  <acronym>SEQUOIA</acronym>
  <official_title>A Placebo-Controlled, Multi-dose, Phase 2/3 Study to Determine the Safety, Tolerability and Effect on Liver Histologic Parameters in Response to ARO-AAT in Patients With Alpha-1 Antitrypsin Deficiency (AATD) [SEQUOIA]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arrowhead Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arrowhead Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of AROAAT2001 (SEQUOIA) is to evaluate the safety, tolerability and effect on
      liver histologic parameters with administration of the investigational product, ARO-AAT, in
      participants with alpha-1 antitrypsin deficiency (AATD). Participants will receive multiple
      subcutaneous doses of ARO-AAT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Part A, participants will be enrolled to receive multiple doses of ARO-AAT or placebo at
      varying dose levels. Once Part A is complete, a single dose level for Part B will be selected
      based on safety and pharmacodynamic parameters from Part A. Patients enrolled into Part A
      will roll over to the Part B dose level or continue to receive placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2019</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Percentage Change From Baseline in Soluble Liver Z-Alpha-1 Antitrypsin (Z-AAT), insoluble liver Z-AAT Levels at Day 113</measure>
    <time_frame>Baseline, Day 113</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Percentage Change From Baseline in Serum AAT Levels at Day 113</measure>
    <time_frame>Baseline, Day 113</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A:Number of Participants with Adverse Events (AEs) Possibly or Probably Related to Treatment</measure>
    <time_frame>Up to Day 113</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B:Number of Participants Achieving a 2-Point Improvement in a Histologic Grading Scale of AATD Associated Liver Disease AND No Worsening of Liver Fibrosis Based on Ishak Score</measure>
    <time_frame>End of Study Biopsy (84 days +/- 14 days after last Part B dose)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part B: Change from Baseline Over Time in a Histologic Grading Scale of AATD Associated Liver Disease</measure>
    <time_frame>Baseline, End of Study Biopsy (84 days +/- 14 days after last Part B dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of Participants with Ishak Fibrosis Stage 1 or Greater Achieving at Least a 1-Stage Improvement</measure>
    <time_frame>End of Study Biopsy (84 days +/- 14 days after last Part B dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change from Baseline Over Time in Ishak Fibrosis Score</measure>
    <time_frame>Baseline, End of Study Biopsy (84 days +/- 14 days after last Part B dose)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of Participants with AEs Possibly or Probably Related to Treatment</measure>
    <time_frame>Up Through End of Study Biopsy (84 days +/- 14 days after last Part B dose)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Alpha 1-Antitrypsin Deficiency</condition>
  <arm_group>
    <arm_group_label>ARO-AAT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: administered on Days 1, 29 and 113 and every 84 days thereafter until dose selected for Part B
Part B: minimum of 6, maximum of 9 doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part A: administered on Days 1, 29 and 113 and every 84 days thereafter until dose selected for Part B
Part B: minimum of 6, maximum of 9 doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARO-AAT Injection</intervention_name>
    <description>solution for subcutaneous (sc) injection</description>
    <arm_group_label>ARO-AAT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>sterile normal saline (0.9% NaCl), calculated to match active comparator, for sc injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of AATD

          -  Liver biopsy at Screening indicating liver fibrosis

          -  Women of childbearing potential must have a negative pregnancy test, cannot be
             breastfeeding, and must be willing to use contraception

          -  Willing to provide written informed consent and to comply with study requirements

          -  Non-smoker for at least 1 year

          -  No abnormal finding of clinical relevance at Screening

        Exclusion Criteria:

          -  Clinically significant health concerns other than AATD

          -  Previous diagnosis or diagnosis at Screening of definitive liver cirrhosis

          -  Previous lung or liver transplant due to AATD

          -  Regular use of alcohol within one month prior to Screening

          -  Use of an investigational agent or device within 30 days prior to dosing or current
             participation in an investigational study involving therapeutic intervention

          -  Use of illicit drugs within 1 year prior to Screening

        NOTE: additional inclusion/exclusion criteria may apply, per protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Monitor</last_name>
    <phone>626-304-3400</phone>
    <email>medicalmonitor@arrowheadpharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakesha Garner</last_name>
      <phone>205-934-1224</phone>
      <email>rgarner@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Brendan McGuire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katrina Stanchfield</last_name>
      <phone>480-342-6055</phone>
      <email>stanchfield.katrina@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Hugo Vargas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego Altman Clinical and Translational Research Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shirin Bassirian</last_name>
      <phone>858-246-2256</phone>
      <email>sbassirian@ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Rohit Loomba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA David Geffen School of Medicine, Center for Health Sciences</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miguel Villarreal</last_name>
      <email>miguelvillarreal@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Igor Barjaktarevic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Tham</last_name>
      <phone>916-734-3351</phone>
      <email>ttham@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Brooks Kuhn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center Benioff Children's Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Camille Langlois</last_name>
      <phone>415-476-1756</phone>
      <email>camille.langlois@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Philip Rosenthal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Health Care</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Swati Toppo</last_name>
      <phone>650-497-4151</phone>
      <email>stoppo@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Kwo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida Hepatology Research at CTRB</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angie Bauer, RN</last_name>
      <phone>352-273-9512</phone>
      <email>bauera@medicine.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Virginia Clark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bruce W. Carter Department of Veteran Affairs Medical Center, University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Rebolledo</last_name>
      <phone>305-243-2568</phone>
      <email>prebolledo@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Campos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monique Williams, RN</last_name>
      <phone>773-702-4477</phone>
      <email>mwillia3@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Gautham Reddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Health University Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holly King</last_name>
      <phone>317-278-6200</phone>
      <email>hrking1@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Raj Vuppalanchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donna Evans, RN</last_name>
      <phone>319-353-4574</phone>
      <email>donna-evans@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Arvind Murali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SSM-Health Cardinal Glennon Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacqueline Cerkoski</last_name>
      <phone>413-577-5611</phone>
      <email>jacqueline.cerkoski@health.slu.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Teckman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Fonseca</last_name>
      <phone>212-305-3745</phone>
      <email>lf2560@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Monica Goldklang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwen Blanton</last_name>
      <phone>843-792-8438</phone>
      <email>blantonm@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Charlton Strange, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Vozar, RN</last_name>
      <phone>615-936-1745</phone>
      <email>Mary.c.vozar@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Michael Porayko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alyssa Mills</last_name>
      <phone>801-581-3693</phone>
      <email>alyssa.mills@hsc.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Shaun Chandna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inspiration Research</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T3A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jane Duke</last_name>
      <phone>416-994-9602</phone>
      <email>jduke@inspirationresearch.ca</email>
    </contact>
    <contact_backup>
      <last_name>Shinead Callery</last_name>
      <phone>416-944-9602</phone>
      <email>scallery@inspirationresearch.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Ken Chapman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RCSI Education &amp; Research Centre, Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>Dublin 9</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ann Collins</last_name>
      <phone>00353 1 809 3864</phone>
      <email>annmcollins@rcsi.ie</email>
    </contact>
    <investigator>
      <last_name>Gerald McElvaney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federica Albicini</last_name>
      <phone>+ 39 0382 502611</phone>
      <email>federica.albicini@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Angelo Corsico, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Babs de Klerk</last_name>
      <phone>+31 (0)71-5261189</phone>
      <email>b.m.de_klerk@lumc.nl</email>
    </contact>
    <investigator>
      <last_name>Bart van Hoek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Central Do Funchal (Hospital Nelio Mendoca)</name>
      <address>
        <city>Funchal</city>
        <zip>9004-514</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vitor Pereira</last_name>
      <phone>351,962,557,897</phone>
      <email>magnovitorp@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Vitor Pereira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Torrens</last_name>
      <phone>+34 9327 46240</phone>
      <email>mariacadaques52@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Joan Genesca Ferrer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital, Clinical Trial Center</name>
      <address>
        <city>Gothenburg</city>
        <zip>41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annika Johansson</last_name>
      <phone>+46 31 342 74 72</phone>
      <email>annika.mari.johansson@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Johan Waern, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 8, 2019</study_first_submitted>
  <study_first_submitted_qc>May 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 10, 2019</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

